The FDA has not set a date for approval verdicts, with decisions expected on the PMA and NDA expected in the “near future”. Image credit: Shutterstock/William Perugini.

A US Food and Drug Administration (FDA) panel has issued a positive recommendation for Lumicell’s surgical imaging tool for breast cancer detection.

The FDA’s Medical Imaging Drugs Advisory Committee (MIDAC) voted 16-2 in favour of the benefit-risk profile of Lumisight (pegulicianine) – an optical imaging agent used in combo with the company’s direct visualisation system (DVS). Together, the products detect residual cancer in real time during lumpectomy surgery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Though FDA panel recommendations are non-binding, they form a good indication as to which direction the agency will sway when deciding on market approval.

Lumicell’s premarket application (PMA) gained fast track designation in 2020 while the imaging agent’s new drug application (NDA) is under priority review.

The FDA has not set a date for approval verdicts, with decisions expected on the PMA and NDA expected in the “near future”, according to Lumicell.

See Also:

The MIDAC’s positive decision was based on efficacy data from more than 350 patients in a pivotal study (NCT03686215) and safety data from over 700 patients across multiple clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lumicell’s tech includes a hand-held imaging probe, supported by cancer detection software, that can be inserted inside the breast cavity to identify any cancer cells that remain during lumpectomy – otherwise known as breast-conserving surgery.

Surgeons examine margins of excised tissue to ascertain whether all cancer cells have been removed, though a proportion of lumpectomies only have margin results a few days after surgery. Lumicell says that, with its system, surgeons will be able to detect residual cancer during the initial lumpectomy in real time.

Lumicell’s device gained fast track designation in 2020, whilst the imaging agent’s new drug application is under priority review.

The Massachusetts-based company was founded in 2008 after founding CEO David Lee’s wife died of breast cancer. Fellow co-founder Moungi Bawendi won the Nobel Prize in Chemistry last year for work on quantum dots.

Lumicell’s CEO Jorge Ferrer said: “We look forward to working with the FDA as it completes its review of Lumisight’s NDA and Lumicell DVS’ PMA application.”

The global diagnostic imaging market was estimated to be worth nearly $32bn in 2023 and is predicted to grow to over $45bn by 2030, according to a report by GlobalData.

Also in the breast cancer imaging space is Clarix Imaging, which raised $10m to advance its 3D imaging platform last October.